Neuphoria Therapeutics Inc.
NEUP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | -$16 | $24 | $1 |
| % Growth | 100% | -165.6% | 2,130.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$15 | $24 | $0 |
| % Margin | – | 97.9% | 98.9% | 0% |
| R&D Expenses | $6 | $9,000 | $3 | $3 |
| G&A Expenses | $0 | $7,768 | $0 | $0 |
| SG&A Expenses | $3 | $7,768 | $2 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $16,768 | $5 | $7 |
| Operating Income | -$9 | -$1,134 | $19 | -$6 |
| % Margin | – | 7,238.8% | 79.8% | -558.8% |
| Other Income/Exp. Net | -$6 | $287 | -$1 | $3 |
| Pre-Tax Income | -$15 | -$846 | $18 | -$3 |
| Tax Expense | -$0 | -$468 | -$0 | $0 |
| Net Income | -$15 | -$378 | $18 | -$3 |
| % Margin | – | 2,414.3% | 75.1% | -293.2% |
| EPS | -4.41 | -6.77 | 6.55 | -0.008 |
| % Growth | 34.9% | -203.4% | 79,015.7% | – |
| EPS Diluted | -4.41 | -6.77 | 6.55 | -0.008 |
| Weighted Avg Shares Out | 2 | 2 | 234 | 234 |
| Weighted Avg Shares Out Dil | 2 | 2 | 234 | 234 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$15 | -$847 | $18 | -$3 |
| % Margin | – | 5,406.5% | 75.6% | -291.5% |